Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ:HRMY
Want to see HRMY full AI Analyst Report?
HRMY Stock Chart & Stats
$29.99
-$1.07(-3.04%)
At close: 4:00 PM EST
$29.99
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume87.33K
Average Volume (3M)893.73K
Market Cap
$1.79B
Enterprise Value$1.45B
Total Cash (Recent Filing)$640.92M
Total Debt (Recent Filing)$206.51M
Price to Earnings (P/E)12.7
Beta1.08
Next Earnings
Aug 11, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.52
Shares Outstanding57,892,677
10 Day Avg. Volume702,981
30 Day Avg. Volume893,730
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit2.10
Enterprise Value/Ebitda6.20
Forecast
1Y Price Target
$49.50Price Target Upside65.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)3.51
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA strong cash position provides flexibility to fund internal pipeline programs and pursue business development without immediate reliance on external financing.
Label Expansion And Commercial ExecutionLabel expansion to include pediatric cataplexy combined with plans to expand the commercial sales force increases the addressable market and supports sustainable sales growth.
New Product FormulationA new pitolisant formulation has its own patent protection that extends beyond existing patents, creating a protected pathway to broaden the product franchise.
Bears Say
Ongoing Patent LitigationAn unresolved patent challenger and a bench trial over a polymorph patent create legal uncertainty that could enable earlier generic entry and pressure Wakix exclusivity.
Product Concentration RiskWakix remains the company’s primary commercial product, so any erosion of its exclusivity would materially reduce revenue visibility and company valuation.
Profitability And Operating CostsHigher operating expenses and weaker gross margins have lowered earnings expectations and prompted analysts to trim price targets, highlighting margin and spending risk.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $1.79B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 67 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on May 07, 2026. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.695 by -$0.145.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.88.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,892,677 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.55 in its last earnings report, missing expectations of $0.695. Following the earnings report the stock price went down -4.149%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (65.06% Upside)
$49.50 (65.06% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 142.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.09%
12-Months-Change
Fundamentals
Return on Equity
17.19%
Trailing 12-Months
Asset Growth
20.49%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
HRMY Company Deck
HRMY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company with strong commercial momentum (17% revenue growth, reaffirmed $1.0–1.04B guidance), a well-funded balance sheet ($870.5M cash), advancing pipeline programs with near-term milestones (BP-205, pitolisant GR/HD, EPX-100), and an assertive IP defense strategy. Offsetting these positives were higher COGS and a sizable increase in operating expenses driven largely by a $32M upfront license fee, a decline in GAAP net income, muted cash flow for the quarter, ongoing litigation with timing/appeal uncertainty, and Q1 market access headwinds. On balance, highlights—particularly revenue traction, cash runway, and pipeline progress—outweigh the lowlights but the company faces near-term cost, legal and access execution risks.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$49.50
▲(65.06% Upside)
Technical Analysis
Ownership Overview
1.11% Insiders
20.47% Mutual Funds
17.09% Other Institutional Investors
32.70% Public Companies and Individual Investors